Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Interstitial Lung Disease clinical trials
Every US clinical trial registered for Interstitial Lung Disease — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
37 US clinical trials · 27 currently recruiting
The research picture
Interstitial Lung Disease has 37 registered US clinical trials, 27 of them open to new participants right now — about 73% of the total.
- 27
- recruiting participants now
- 73%
- of trials open to enrollment
- 3
- in Phase 3–4 (later-stage)
- 3
- top sponsor: Bastiaan Driehuys
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Pulmonary Fibrosis Foundation Community Registry
Pulmonary Fibrosis Foundation
NCT05382572
WTC Chest CT Imaging Archive
Icahn School of Medicine at Mount Sinai
NCT03295279
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center
NCT05392881
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics
NCT06388421
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
University of Colorado, Denver
NCT03297775
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics
NCT05943535
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
Mayo Clinic
NCT03478826
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
University of Massachusetts, Worcester
NCT06855329
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
University of Colorado, Denver
NCT06397677
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Bastiaan Driehuys
NCT01280994
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
NCT07179380
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics
NCT05776225
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Mario Castro, MD, MPH
NCT04624490
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
Medical University of South Carolina
NCT07269262
129Xe MRI Cardiopulmonary
Bastiaan Driehuys
NCT06038630
Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research
Baylor Research Institute
NCT04664192
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Children's Hospital Medical Center, Cincinnati
NCT04925375
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
National Institute of Environmental Health Sciences (NIEHS)
NCT06325696
Pulmonary Hypertension SOLAR
Bastiaan Driehuys
NCT04778046
FAPI PET for Lung Fibrosis
University of California, Los Angeles
NCT05365802
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health Professions
NCT06304207
Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Massachusetts General Hospital
NCT05417776
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Memorial Sloan Kettering Cancer Center
NCT07323732
Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
Mayo Clinic
NCT05120934
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Pharma
NCT05892614
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Paul Szabolcs
NCT03630211
Feasibility of Semaglutide in Advanced Lung Disease
University of Pennsylvania
NCT05746039
Genentech Validation Tool for Pulmonary Fibrosis
Columbia University
NCT04676594
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT05270668
A Study of Mosliciguat in PH-ILD
Pulmovant
NCT06635850
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Liquidia Technologies
NCT06129240
Autologous Stem Cell Treatment for Chronic Lung Disease Study
Lung Institute
NCT03044431
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Icahn School of Medicine at Mount Sinai
NCT04619680
Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Michael Roth
NCT03221257
Palliative Care Planner (PCplanner)
Duke University
NCT05095363
Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)
Duke University
NCT01972685
Allogeneic Bone Marrow Mesenchymal Stem Cells for Patients With Interstitial Lung Disease (ILD) & Connective Tissue Disorders (CTD)
Mayo Clinic
NCT03929120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 13 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Interstitial Lung Disease Trial Landscape
ClinicalTrials.gov lists 37 US studies indexed under Interstitial Lung Disease, and 27 of those are currently open to recruitment — roughly 73% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Interstitial Lung Disease shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 17 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Interstitial Lung Disease is led by Bastiaan Driehuys with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 37 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Interstitial Lung Disease?
PlainTrial tracks 37 US clinical trials for Interstitial Lung Disease, of which 27 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Interstitial Lung Disease?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.